Which company is Shendafineridone from?

Finerenone (Finerenone) is a drug developed by Bayer AG. Bayer is a global company with core competencies in the life sciences fields of healthcare and nutrition. As a leader in cardiovascular (CV), Bayer maintains its long-term commitment to science for a better life by advancing research and treatment options. Bayer's cardiorenal product portfolio began with the discovery and development of many important therapies and now includes several products and compounds in various stages of preclinical and clinical development with the potential to impact the way cardiovascular and renal diseases are treated.

Finelidone is approved for the treatment of adult chronic kidney disease (CKD) related to type 2 diabetes (T2D). It belongs to a class of drugs called selective mineral receptor antagonists (Mineralocorticoid Receptor Antagonist, referred to as MRA). Its main function is to reduce the impact of the adrenocortical hormone aldosterone by inhibiting the activity of mineral receptors, thereby reducing excessive aldosterone levels in the body. This drug is used to treat proteinuria caused by hypertension in chronic kidney disease and has demonstrated efficacy in preventing heart failure and reducing cardiovascular risk.

Finelidone has been through a series of clinical trials investigating its efficacy (including cardiovascular death and total heart failure events) and safety in patients with symptomatic heart failure with ejection fraction≥40% (HFmrEF/HFpEF). It has obtained drug registration approval in some countries and is marketed as Kerendia in more than 70 countries around the world, including the United States. It is marketed in China under the trade name Keshenda. The development and promotion of this medicine is part of the Bayer Group's ongoing innovation in the field of health, aiming to provide patients with safer and more effective treatment options.